Latest
MolPE CEO Li Xiang Joins Panel Discussion on Real-World Applications of AI for Science
Opens the article in a new tabMolPE CEO Li Xiang was invited to attend the Equator Quadrant 2026 AI Global Future Summit as a panel discussion speaker.
News
Research progress, product updates and industry exchanges at MolPE.
2026
Three Things Pharma Companies Should Do Now That AI Drug Development Has Entered the Five-Year Plan
Opens the article in a new tabOn September 18, ten government departments including the Ministry of Industry and Information Technology and the National Development and Reform Commission jointly issued the "15th Five-Year Plan" for Pharmaceutical Industry Development, marking the first time AI drug development has been listed as a key task in a five-year plan.
MolPE to Take the Stage at Slush Shanghai 2026 Pitch Event
Opens the article in a new tabSelected from over 600 applications, MolPE will pitch live at Slush Shanghai 2026.
See You in Shanghai Next Thursday | Equator Quadrant 2026 AI Innovation Summit
Opens the article in a new tabIf you are also in Shanghai, you are welcome to join us and chat in person.
One Scientist Running as a Team: MolPE's Live Sharing at Kehua Forum
Opens the article in a new tabMolPE presented its practices with the MolEX multi-agent collaboration platform at the event, and also signed a computing power ecosystem agreement.
MolPE Wraps Up Successful Participation in the 8th CMC-China China Pharmaceutical Industry Expo
Opens the article in a new tabMolPE appeared at the AI Roadshow session of the 8th CMC-China, presenting its AI Co-Scientist on stage.
Internship Recruitment: Three Open Positions at MolPE Await You
Opens the article in a new tabAgent Intern, Testing Intern, and Business Intern positions. Location: Shanghai Pudong Software Park.
Opening This Friday! MolPE to Appear at CMC2026 with MediAI Pitch Session
Opens the article in a new tabMolPE will take the stage at 14:00 on September 4 at Hall B, Booth B108, Suzhou International Expo Center.
Global First AI Antibody Blind Test Results Released: AI Beats Wet Lab
Opens the article in a new tabComputational design is shifting from an auxiliary reference to a primary source of output.
mRNA Vaccine Succeeds in Phase III, Ushering in the Era of AI-Designed Molecules
Opens the article in a new tabRecurrence risk reduced by 49%, making personalized medicine—one drug per person—a reality.
34 Forums, 5 Tasks, 1 Direction: Industry Association Observations from a Member's Perspective
Opens the article in a new tabMolPE attended the conference as a member of the Shanghai Biopharmaceutical Industry Association and shares several industry signals gleaned from the data presented at the meeting.
MolPE Advances to National Top 30 in China's "AI+" Innovation Finals
Opens the article in a new tabOnly 10 spots were available in the AI + Healthcare track, and MolPE secured one of them.
When Embodied AI Meets Large Models, AI Drug Discovery Gets a Lab-Scale Problem
Opens the article in a new tabAt the Zhangjiang AI Industry Salon, four tracks shared the stage to discuss "full-domain penetration."
First Batch of MolEX Agent Trial Slots Now Open
Opens the article in a new tabGet hands-on experience with MolEX's multi-property simultaneous optimization capabilities.
From $400M Financing to Two Breakthroughs in 30 Days: AI Macromolecule Design Enters Its Delivery Era
Opens the article in a new tabThe AI macromolecule design sector is seeing a surge of activity.
From February to July: A Policy "Triple Jump" for AI Drug Discovery
Opens the article in a new tabThe State Council's latest document mentions "innovative drugs" seven times, and AI drug discovery companies may lead national research projects.
MolPE to Appear at BEYOND Expo Innovation Summit on July 4
Opens the article in a new tabLi Xiang, CEO of MolPE, has been officially invited to attend the AI + Smart Hardware Summit of BEYOND EXPO in Hangzhou on July 4 as a key roundtable panelist.
AI for Science: From National Strategy to Industrial Implementation, A Paradigm-Shifting Transformation in Scientific Research Is Underway
Opens the article in a new tabDriven by the resonance of policy, market, and technology, AI for Science is no longer a cutting-edge concept but a wave that is reshaping the global landscape of scientific research and industry.
MolPE Wins Second Prize at the 2026 Yangcheng Lake Maker Competition AI and Intelligent Manufacturing Session
Opens the article in a new tabMolPE's AI-driven solution for large-molecule drug development, featuring simultaneous multi-property optimization, has again won authoritative industry recognition.
As AI Antibody Design Turns to Developability, Multi-Property Simultaneous Optimization Emerges as the Key Answer
Opens the article in a new tabA look at the next frontier of AI antibody design through the Chai-2 paper.
Simultaneous Multi-Property Optimization: The True Watershed for AI Antibody Design
Opens the article in a new tabHow AI-designed antibodies can escape the trap of single-property optimization and achieve coordinated targets across multiple properties.
5-Day Countdown | BEYOND Expo 2026 Full Agenda Released
Opens the article in a new tabBEYOND Expo 2026 may be the must-attend tech event of the year!
MolPE × BEYOND 2026: See You in Macao!
Opens the article in a new tabMolPE has prepared 20 visitor passes, valued at RMB 499 each, all given away for free — don't miss out!
Registration Closes Tomorrow: 7th Small-Molecule New Drug R&D and AI Drug Design Forum — PROTAC, Molecular Glues, and AI Drug Design
Opens the article in a new tabLi Xiang, CEO of MolPE, has been invited to attend IDC 2026 and will deliver a speech at the AI-Assisted Small-Molecule New Drug R&D Forum.
MolPE CEO Li Xiang to Speak at IDC2026
Opens the article in a new tabTen free passes are open for application, with review-based registration closing on May 15.
See You in Hong Kong, May 11–12!
Opens the article in a new tabFind us at booth ASGH 3F-A09 to talk technology, explore partnerships, and shape the future of new drug discovery together.
West China Hospital's Ai Jianzhong and Yang Lu Teams Join Peng Jiajie's Team at Northwestern Polytechnical University to Identify a Novel ALKBH5-Regulated Ferroptosis Mechanism in Prostate Cancer via Large Language Model
Opens the article in a new tabThis study developed a large language model integrating hierarchical expert knowledge (HKLLM-RG), identified ALKBH5 as a key risk factor, elucidated the molecular mechanism by which ALKBH5 regulates CHRM3/ZNF281 signaling to promote ferroptosis, and proposed a combination therapy strategy targeting this pathway, providing a new therapeutic target for prostate cancer.
Nat. Comput. Sci. | A Two-Stage Generative Optimization Framework for Therapeutic Antibody Design
Opens the article in a new tabTranslating therapeutic antibodies such as DRUGONE into clinical use requires balancing multiple key properties, including antigen-binding specificity, viscosity, clearance, and immunogenicity, yet existing methods often rely on multi-step screening or single-objective optimization and struggle to address these complex properties simultaneously. Researchers propose DualGPT-AB, a two-stage…
No More Letting AI "Guess" Molecules: A BIONNOVA Talk on What Real Drug Design Means
Opens the article in a new tabFrom NTP to NSP, from screening to design—MolEX and the end of the "impossible triangle."
What Is the 'Agent' Mentioned in the State Council Document, and Why Does It Deserve More Attention Than Large Models?
Opens the article in a new tabWhy has the state specifically singled out 'agents'? What technological judgment and industrial planning lie behind this?
5-Day Countdown: MolPE to Unveil New Product at BIONNOVA 2026
Opens the article in a new tabMolPE will make the first public debut of its new AI drug discovery platform product, and CEO Li Xiang will deliver a keynote speech at the "Frontiers of Next-Generation Antibody Therapeutics" forum.
MolPE Invitation | Free Limited Tickets for the 7th BIONNOVA, While Stocks Last
Opens the article in a new tabScan the QR code to get a free ticket to the 7th BIONNOVA exhibition!
Cell Therapy, AI Standards, and a New Special Committee: What MolPE Saw at the Conference
Opens the article in a new tabMolPE will not only pursue its own technological breakthroughs, but also actively participate in industry standard discussions and academia-industry exchanges, working with association members to explore the "Shanghai Model" of AI plus biopharmaceuticals.
AI Drug Discovery Milestones: Computing Power Arms Race Escalates as Industry Sees First Profitability Breakthrough
Opens the article in a new tabRoche overtakes Eli Lilly as AI drug discovery moves from 'storytelling' into a new cycle of 'competing on resources'; XtalPi Holdings turned profitable, becoming the first profitable AI drug discovery stock listed in Hong Kong. These two events, from two dimensions, together mark the arrival of an industry inflection point.
Two Sessions Set the Tone for the Start of the 15th Five-Year Plan: Does AI Drug Discovery Take Center Stage? — Focus on Frontier Tracks to Break Through Bottleneck Technologies
Opens the article in a new tabDelegates and committee members heatedly discussed biologics, synthetic biology, and AI drug discovery, injecting a boost into innovative drugs.
Behind the BD Boom: What Are Buyers Really Paying For? Not Just Assets, but Certainty
Opens the article in a new tabMNCs are willing to pay high premiums for quality assets, with upfront payments in China's innovative drug BD deals soaring to $172 million — what is the logic behind this?
A Booming Spring Festival Season: AI Drug Discovery Is Moving from Storytelling to Working Miracles
Opens the article in a new tabReviewing the positive industry developments at the start of 2026, we identified four clear paths.
Shanghai's 15th Five-Year Plan Released: The Golden Age of AI Drug Discovery and Macromolecule Innovation Is Here
Opens the article in a new tabShanghai's blueprint for the next five years has been unveiled. As national strategy, industry momentum, and cutting-edge technologies converge, a wave of innovation in China's AI-driven drug discovery is surging forward.
From the Jungle of Oncology Innovation to the Blue Ocean of Precision: Annual Value Review of the Global Top 10 Targets
Opens the article in a new tabAs someone playing the dual role of BD and CMO, needing both to discern the essence of science and to balance business realities, my task is to distill actionable strategic pathways from ecosystem data.
Three Biotech Trends to Watch in 2026: Who Will Ignite the Market?
Opens the article in a new tabIn 2026, three technologies—IO 2.0, ADCs, and small nucleic acid drugs—will reach critical turning points. How do they work? What is their current progress? And who will lead the market?
Is a Technological Singularity Nearing for Pharma? Three Trends in 2026 Are Accelerating the Disruption of Traditional R&D
Opens the article in a new tabAI-designed molecules, nucleic acid drugs for common diseases, and oral formulations replacing injections are comprehensively breaking the boundaries of traditional drug R&D.
CMO on BD Case Study: Why Did AbbVie Choose Rongchang's Bispecific Antibody — A Keen Eye or a Forced Choice?
Opens the article in a new tabThe partnership between Rongchang and AbbVie has set a benchmark of 'differentiated innovation plus global collaboration' for China's innovative drugs. It is not only a commercial success but also a microcosm of China's biopharmaceutical industry moving from 'following' to 'running alongside' — and AI is quietly rewriting the rules of the game.
Insilico Medicine's Double Win: After the IPO Wave, How Will AI Drug Discovery Unleash a Surge of Value?
Opens the article in a new tabInsilico Medicine's IPO and major partnership have set a new value benchmark for the AI drug discovery industry. This is not just the success of a single company, but a key turning point for the entire industry as it moves from technological exploration to value creation.
2025
2026: A Year of Upheaval for AI Drug Discovery — Are We Ready?
Opens the article in a new tab2026 will be the year that separates the real players from the rest — only those whose technology can be implemented, and who can truly help pharmaceutical companies shorten timelines and cut costs, will survive, or even thrive. We are still on the way. But one thing is certain: this industry needs not just technology companies, but partners who understand R&D, understand real-world scenarios, and can fight side by side.
Momentum, Breakthrough, Growth: MolPE 2025 Annual Review
Opens the article in a new tabA paradigm shift in drug discovery has arrived—from experience-driven trial and error to data-driven rational design. Standing at this historic inflection point, MolPE is committed to becoming a foundational builder of next-generation drug discovery. We are not just developing tools, but working alongside industry pioneers to redefine how drugs are invented.
MolPE Named to InfoQ Annual List, AI Drug Discovery Solution Honored as 'Best Industry Implementation'
Opens the article in a new tabWhen an authoritative technology list awarded MolPE the 'Best Industry Implementation,' it was not only an honor but also a 'feasibility validation report' from the industry.
Dr. Huang Qiang, Senior Clinical Development Expert, Joins MolPE as Chief Medical Officer
Opens the article in a new tabWe warmly welcome Dr. Huang Qiang to MolPE as Chief Medical Officer. Dr. Huang is a rare composite leader in China's biopharmaceutical industry, combining top-tier clinical vision, deep R&D experience, and outstanding business insight.
MolPE Wins 2025 "Innovation in Shanghai" Team Excellence Award Among 7,000 Projects
Opens the article in a new tabThe award represents strong strategic recognition from the industry of MolPE's technological approach and commercial prospects of "reshaping drug R&D paradigms with AI."
MolPE Wins Excellence Award at the First 'AI Hangzhou, Code the Future' Competition
Opens the article in a new tabThis award not only recognizes the technical strength of the MolPE team, but also affirms the company's precise positioning in the 'AI + biopharmaceutical' strategic track and its active integration into the high-end innovation ecosystem.
MolPE Wins First Prize at CCF Innovation Competition, China's Most Authoritative IT Organization
Opens the article in a new tabMolPE won the national first prize in the CCF "AI + Healthcare" track with its MolPE BioX intelligent drug platform. This is not only an honor, but also an authoritative endorsement from the source of technology.
AI Empowers Biologics: GB-0895 Phase III Trial Launches, Marking Dual Breakthroughs in Asthma Treatment and Industry Transformation
Opens the article in a new tabAI is no longer just an auxiliary tool, but a key driver of drug iteration and value creation. MolPE is committed to leveraging its AI platform and algorithms to bring greater certainty to more R&D pipelines and jointly advance biologics development into a precise, efficient, and intelligent era.
MolPE Joins Chinese Antibody Society's mAbTalk China Debut
Opens the article in a new tabLooking ahead, MolPE will continue to leverage the Society's platform to deepen its work in AI-driven drug discovery, working alongside peers to ride this 'Eastern wave' and help Chinese antibody therapies shine even more brightly on the global innovation stage.
MolPE Officially Joins Shanghai Biopharmaceutical Industry Association (SBIA) as Member
Opens the article in a new tabMolPE has recently been admitted to the Shanghai Biopharmaceutical Industry Association (SBIA) as a certified member, an official recognition marking strong support from an authoritative industry platform for the company's development in the biopharmaceutical field.
MolPE Officially Certified as Member of Zhejiang Blockchain Technology Application Association
Opens the article in a new tabMolPE was invited to attend the accreditation ceremony and received certification as a member unit of the Zhejiang Blockchain Technology Application Association, gaining official recognition and endorsement from an industry platform.
MolPE Showcases AI Drug Discovery Solutions at WeStart Online Roadshow
Opens the article in a new tabAt the recent WeStart Hard-Tech Starlink biomedical online investment matchmaking event, MolPE presented its core AI drug discovery technology, joining pioneering projects across fields in demonstrating the innovative vitality of biomedicine integrated with hard tech.
MolPE Showcases AI-Driven Drug R&D at CIIE, Winning Official and Market Recognition
Opens the article in a new tabMolPE was invited to participate in the CIIE. As an innovative company focused on AI-driven biopharmaceutical R&D, MolPE presented its core product, the MolPE BioX intelligent drug platform, demonstrating its expertise in developing innovative therapies for cancer and autoimmune diseases.
How Can AI Break the "Impossible Triangle" in Macromolecular Drug R&D?
Opens the article in a new tabTraditional macromolecular drug development faces core pain points: 10–15 year R&D cycles, over $2 billion in investment, less than 10% clinical success rate, and the "impossible triangle" dilemma where optimizing one property necessarily sacrifices others.
China's 15th Five-Year Plan Focuses on Biomanufacturing to Rebuild High-Tech Industry in Next Decade; MolPE Ready to Seize the Opportunity
Opens the article in a new tabThe 15th Five-Year Plan proposes forward-looking deployment of future industries and promoting biomanufacturing as a new economic growth point, aiming to rebuild a China high-tech industry over the next 10 years. This represents a major policy dividend for companies deeply engaged in biotechnology.
MolPE's Roadshow Achievements Draw Attention at International Eye Health Summit
Opens the article in a new tabMolPE CEO Li Xiang was invited to attend and present at the International Eye Health Technology Innovation and Industry Development Summit Forum, detailing the solutions of MolPE's AI bio-drug platform: leveraging a patented multi-property simultaneous optimization technology, the platform can simultaneously optimize the affinity of ophthalmic antibody drugs (such as anti-VEGF drugs)
Three AI Drug Discovery Breakthroughs in the Next Three Years: How Can Small and Mid-Sized Pharma Companies Seize the Opportunity?
Opens the article in a new tabOver the next three years, the key to success in AI-driven drug discovery lies in leveraging one's own resources to seize emerging breakthroughs. By focusing on lightweight approaches such as multimodal SaaS integration, drug repositioning, and virtual toxicity prediction, small and mid-sized pharmaceutical companies can achieve nimble, high-value breakthroughs in the AI wave.
In Conversation with MolPE CEO: Unlocking the Present and Future of AI Drug Discovery
Opens the article in a new tabMolPE founder and CEO Li Xiang will break down industry pain points, explain how AI can drive down traditional pharmaceutical costs, assess the current stage of the sector, and share how the company is leveraging AI for Science policy dividends to accelerate anticancer drug development.
MolPE Showcases AI Solutions for Pharma Efficiency at the Global Digital Trade Expo
Opens the article in a new tabMolPE presents its core products at booth 7B-B041 in the AI zone of the Global Digital Trade Expo.
Reshaping Drug R&D Paradigm with AI to Unlock Accelerated Innovation in Biomedicine
Opens the article in a new tabLi Xiang, founder and CEO of MolPE, was invited to attend and delivered a talk titled "AI Empowering Biomedicine: Technological Breakthroughs, Industry Applications, and Future Trends." Drawing on industry trends, technical breakthroughs, and real-world case studies, he shared in-depth and forward-looking insights with over 80 biomedicine professionals, researchers, and investor representatives on site.
Strategic Partnership: MolPE and Huasikang Bio to Build a Biopharmaceutical Innovation Ecosystem
Opens the article in a new tabThe two parties will join hands to create a more competitive partnership model and contribute to innovation breakthroughs in the biopharmaceutical industry, unlocking new vitality with intelligence and innovation.
MolPE and Pharmcube Announce Strategic Partnership to Explore AI-Empowered Possibilities in Pharma
Opens the article in a new tabThe two parties are expected to engage in in-depth cooperation across multiple dimensions, including pharmaceutical R&D and data applications, jointly exploring how AI can better serve the pharmaceutical industry and driving it toward a smarter and more efficient future.
Joint Research Program: MolPE × Northwestern Polytechnical University to Deepen Industry-Academia Integration
Opens the article in a new tabFrom innovative sparks in the laboratory to practical applications in industry, this strategic partnership will break down barriers between research and industry, accelerate the translation of technological achievements, and inject strong momentum into the industry's innovation and development.
MolPE Launch Celebration and MolPE Biox Intelligent Drug Platform Release Successfully Held
Opens the article in a new tabMolPE will join hands with more partners to create value through technology and connect the world with intelligence, bringing the fruits of AI-powered drug development to benefit countless households and writing a brilliant chapter in the intelligent development of the biopharmaceutical industry.
Countdown: 5 Days to Go — Guide to the "Intelligence Ignites the Future, Innovation Creates New Life" Launch Event
Opens the article in a new tabThe "Intelligence Ignites the Future, Innovation Creates New Life" event — MolPE's opening ceremony and MolPE Biox product launch — will be grandly held on September 17, 2025, at Shanghai Pudong Software Park.
Invitation to MolPE's Opening Ceremony and MolPE Biox Product Launch: Shaping the Future with Intelligence and Innovation
Opens the article in a new tabAct now — scan the QR code below to register!
A Letter to Pharmaceutical Colleagues: Using AI to End the '10 Years, $1 Billion' R&D Dilemma
Opens the article in a new tabAs we decode proteins with code and accelerate cures with algorithms, I firmly believe the next 'drug hero' will no longer be a lone champion, but a symbiosis of AI and human wisdom. We look forward to joining hands with you to turn the 'impossible' into the 'norm'.
WeChat official account
Scan to follow our research and product updates.